November 17 FDA Meeting Set to Discuss Dosing and Trial Size for Second Drug in Pipeline
DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts.
NeOnc says it plans to seek FDA feedback on NEO212’s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a marketing application. The company also intends to discuss a potential registrational strategy and whether a proposed Phase 2 design could potentially support an accelerated-approval pathway; marking a meaningful transition from dose-finding toward the next stage of clinical development.
NEO212 enters that meeting with some intriguing, though still preliminary, human data.
During Phase 1, dose escalation reached the protocol-defined maximum tolerated dose at 810 mg, after which the recommended Phase 2 dose was established at 610 mg. The company has highlighted a patient with recurrent IDH1 wild-type, MGMT-methylated glioblastoma who experienced an approximately 60% tumor reduction and 21 months of disease control. Another heavily pretreated patient with lung cancer metastatic to the brain experienced stable disease for approximately 16 months. These are individual patient observations, not proof of efficacy, and larger trials will have to determine whether the results can be replicated.
NeOnc CEO Amir Heshmatpour put the immediate objective plainly: “This meeting will help us understand FDA’s feedback on the population, study design and endpoints for the next stage of development.”
The NEO212 catalyst arrives as the broader NeOnc story is also attracting Wall Street attention. Roth Capital recently initiated coverage of NeOnc with a $20 price target, with analyst Jonathan Aschoff reportedly anticipating potential pivotal-trial starts by the end of 2026.
NeOnc is now advancing two potential therapies in its CNS cancer pipeline, giving investors more than one clinical catalyst to watch. Its lead program, NEO100, recently generated topline Phase 2a data in recurrent IDH1-mutant high-grade glioma, with the company reporting six-month progression-free survival of 48.9% versus a prespecified 20% benchmark and median overall survival of 26.09 months. NeOnc said it plans to engage with the FDA regarding a potential registrational pathway.
The parallel development tracks could give NeOnc multiple potential catalysts heading into 2027. Roth Capital’s research indicates Aschoff expects an FDA Type B End-of-Phase 2 meeting for NEO100 in October and sees potential pivotal-trial starts before the end of 2026.
Meanwhile, NeOnc has raised capital from institutional investors, including a September registered direct offering priced at $4.20 per share and accompanying warrants. Company insiders have also been active buyers: SEC filings show recent open-market purchases by executives including Heshmatpour and Thomas C. Chen.
That backdrop makes November 17 particularly interesting. NTHI is approaching the FDA with a defined Phase 2 dose, early signals of clinical activity and a stated ambition to develop NEO212 across difficult-to-treat CNS cancers.
If the agency provides a workable path forward on population, endpoints and study design, NEO212 could emerge from the meeting with a substantially clearer development roadmap.
For NTHI shareholders, November 17 is therefore less about expecting an approval and more about watching whether the FDA conversation turns NEO212 from an intriguing clinical program into a more clearly defined late-stage development story.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
